How much? Pfiz­er ex­pects to reap at least $26B from Covid vac­cine in 2021

Pfiz­er’s Covid-19 vac­cine is like­ly to bring in about $26 bil­lion in 2021 rev­enues, which is more than $10 bil­lion more than the bio­phar­ma be­he­moth pre­vi­ous­ly pre­dict­ed, the com­pa­ny an­nounced Tues­day morn­ing.

The com­pa­ny said that fig­ure is based on signed con­tracts as of mid-April that amount to 1.6 bil­lion dos­es of the vac­cine to be de­liv­ered this year. And the dra­mat­ic uptick in guid­ance is due to ad­di­tion­al sup­ply agree­ments that have been signed since the com­pa­ny’s pre­vi­ous guid­ance. More may be com­ing too.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER